pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

217 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • <![CDATA[Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer]]>
    <![CDATA[Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.]]>
    <![CDATA[Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease]]>
    <![CDATA[The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.]]>
← prev
page 8 of 9
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago↗ source
  • <![CDATA[ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies]]>
    <![CDATA[Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026]]>
    <![CDATA[Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Targeted Therapy Sequencing After Resistance in NSCLC]]>
    <![CDATA[Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations]]>
    <![CDATA[Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA]]>
    <![CDATA[Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response]]>
    <![CDATA[Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Reigniting Your Curiosity During Fellowship ]]>
    <![CDATA[Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ]]>
    <![CDATA[R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]>
    <![CDATA[Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC]]>
    <![CDATA[Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma]]>
    <![CDATA[Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC]]>
    <![CDATA[An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma]]>
    <![CDATA[Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Sznol on Biomarkers of Response in Metastatic Melanoma]]>
    <![CDATA[Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>
    <![CDATA[The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go]]>
    <![CDATA[Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management]]>
    <![CDATA[Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]>
    <![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>
    onclive · 2mo ago↗ source